Aspira Women's Health Inc. (AWH)
| Market Cap | 41.85M |
| Revenue (ttm) | 9.15M |
| Net Income (ttm) | -16.69M |
| Shares Out | 12.34M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,802 |
| Open | 3.510 |
| Previous Close | 3.500 |
| Day's Range | 3.390 - 3.520 |
| 52-Week Range | 2.310 - 6.750 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 4.45 (+31.27%) |
| Earnings Date | May 9, 2024 |
About AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endoc... [Read more]
Financial Performance
In 2023, AWH's revenue was $9.15 million, an increase of 11.85% compared to the previous year's $8.18 million. Losses were -$16.69 million, -44.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AWH stock is "Buy." The 12-month stock price forecast is $4.45, which is an increase of 31.27% from the latest price.
News
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, a...
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter an...
Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gyne...
Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gyne...
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...
Aspira Women's Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...
Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...
Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...
Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma
Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company foc...
Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period
Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-...
Aspira Women's Health to Present at the BioVenture Nexus Conference
The conference is taking place on October 5-6, 2023, in Los Angeles, CA The conference is taking place on October 5-6, 2023, in Los Angeles, CA
Aspira Women's Health Signs Exclusive Sample Procurement Agreement with The University of Oxford
Samples to be used in validating the Company's EndoCheck SM test in development for the diagnosis of endometriosis
Aspira Women's Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations
AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women's health diagnostic t...
Aspira Women's Health® Reports Second Quarter 2023 Financial Results
Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.
Aspira Women's Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer
AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...
Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023
AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools...
Aspira Women's Health Regained Compliance with Nasdaq's Minimum Bid Price Requirement
AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...
Aspira Women's Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health to Participate at William Blair's 43rd Annual Growth Stock Conference
AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...
Aspira Women's Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health Names Torsten Hombeck as Chief Financial Officer
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023
AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...